Details of the Drug

General Information of Drug (ID: DM4I1JP)

Drug Name

Polyethylene glycol

Synonyms

ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F

Indication

Disease Entry	ICD 11	Status	REF
Constipation	DD91.1	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

62.07

Topological Polar Surface Area (xlogp)

-1.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2.7 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3 h [2]
Elimination: 85% to 99% of the compound was excreted in the feces [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.1 hours [2]
Metabolism: The drug is not metabolised [3]
Vd: The volume of distribution (Vd) of drug is 48,481 L [2]

Chemical Identifiers

Formula: C2H6O2
IUPAC Name: ethane-1,2-diol
Canonical SMILES: C(CO)O
InChI: InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2
InChIKey: LYCAIKOWRPUZTN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 174
ChEBI ID: CHEBI:30742
CAS Number: 107-21-1
DrugBank ID: DB09287
TTD ID: D0IV3M
INTEDE ID: DR1312

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Alcohol dehydrogenase class-III (ADH5)_{Main DME}	DEIOH6A	ADHX_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Polyethylene glycol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Ivosidenib.	Acute myeloid leukaemia [2A60]	[7]
Arn-509	DMT81LZ	Moderate	Increased risk of lowers seizure threshold by the combination of Polyethylene glycol and Arn-509.	Acute myeloid leukaemia [2A60]	[8]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Gilteritinib.	Acute myeloid leukaemia [2A60]	[7]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Oliceridine.	Acute pain [MG31]	[8]
ABT-492	DMJFD2I	Moderate	Increased risk of lowers seizure threshold by the combination of Polyethylene glycol and ABT-492.	Bacterial infection [1A00-1C4Z]	[9]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[7]
Osilodrostat	DMIJC9X	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Osilodrostat.	Cushing syndrome [5A70]	[7]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Deutetrabenazine.	Dystonic disorder [8A02]	[7]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Ingrezza.	Dystonic disorder [8A02]	[7]
Fostemsavir	DM50ILT	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Amifampridine	DMK08L3	Moderate	Increased risk of lowers seizure threshold by the combination of Polyethylene glycol and Amifampridine.	Lambert-Eaton syndrome [8C62]	[9]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Osimertinib.	Lung cancer [2C25]	[7]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Selpercatinib.	Lung cancer [2C25]	[7]
LGX818	DMNQXV8	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and LGX818.	Melanoma [2C30]	[7]
Siponimod	DM2R86O	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Siponimod.	Multiple sclerosis [8A40]	[7]
Ozanimod	DMT6AM2	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Ozanimod.	Multiple sclerosis [8A40]	[7]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Entrectinib.	Non-small cell lung cancer [2C25]	[7]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Rucaparib.	Ovarian cancer [2C73]	[7]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Triclabendazole.	Parasitic worm infestation [1F90]	[7]
Macimorelin	DMQYJIR	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[7]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Lefamulin.	Pneumonia [CA40]	[7]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Relugolix.	Prostate cancer [2C82]	[7]
LEE011	DMMX75K	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[7]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Polyethylene glycol and Pitolisant.	Somnolence [MG42]	[7]
-----------


⏷ Show the Full List of 24 DDI Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	PLENVU (polyethylene glycol 3350, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) US FDA 2018 Label
3	Bicalho B, Guzzo GC, Lilla S, Dos Santos HO, Mendes GD, Caliendo G, Perissutti E, Aiello A, Luciano P, Santagada V, Pereira AS, De Nucci G: Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. Curr Drug Metab. 2005 Dec;6(6):519-29.
4	PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007 Jan;35(1):9-16.
5	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
6	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
7	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8	Canadian Pharmacists Association.
9	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
10	Cerner Multum, Inc. "Australian Product Information.".